A Historical Milestone: The First Spanish Public-Private Pharmaceutical Company is Born
In an unprecedented step, the Government of Spain, together with the pharmaceutical giants Rovi and Insud Pharma, has given life to Terafront Farmatech, a commercial company destined to transform the country’s pharmaceutical landscape.
The Momentum of the Ministry of Science
Under the leadership of the Minister of Science, Diana Morant, the Ministry of Science has been the driving force behind this innovative project, which is part of the ambitious Vanguard Strategic Health Plan (Perte de Salud).
A Strategic Alliance to Accelerate Pharmaceutical Development
Terafront Farmatech was born from the union of forces between the State, represented by Innvierte, and the private companies Rovi and Insud Pharma. This strategic alliance aims to accelerate the production of medicines, therapies and advanced technologies in Spain.
Ambitious Goals: Two Advanced Therapies by 2027
Terafront Farmatech has set ambitious goals for the coming years. Among them, the authorization and commercialization of two advanced therapies stands out by 2027, which would represent a significant advance in the treatment of complex diseases.
A Solid Corporate Structure
The commercial company is chaired by Insud Pharma, while Rovi and Innvierte act as directors. The management team is made up of highly qualified professionals, including Francisco Javier Pérez Torrijos as non-board secretary.
Financing: A Joint Investment for the Future
Terafront Farmatech will have a capitalization of 74.87 million euros at the end of 2024. The State, through Innvierte, will contribute 36.68 million euros, while private laboratories will contribute 38.18 million.
A Transformative Project for Spanish Health
Terafront Farmatech is more than just a commercial company. It is a transformative project that aims to improve the health of Spanish citizens, promote pharmaceutical innovation and position Spain as a benchmark in the sector.
